Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HHS Message On Value-Based Drug Pricing Complicated But Themes Emerging

Executive Summary

US government involvement in value assessments for prescription drugs and the benefits of outcomes-based contracting in lowering drug prices are among the issues being discussed.

You may also be interested in...



Gottlieb Shifts From Regulatory To Reimbursement Focus In One Of First Post-Commissioner Appearances

CAR-T reimbursement is concern for former US FDA commissioner Scott Gottlieb in speech at the National Press Club.

Rx Importation: Califf's Switch Means US FDA Commissioners No Longer Uniformly Opposed

In JAMA editorial, former FDA chief supports drug importation under narrow circumstances as a way to reduce drug prices, marking a shift from his previous stance on the issue and that of other past agency heads. Essay, co-authored by former CMS Acting Administrator Andy Slavitt, calls importation "a workaround born of desperation." 

Brilinta Value-Based Contract With UPMC Incorporates Two-Sided Risk

AstraZeneca and UPMC Health Plan have signed a value-based contract for Brilinta linked to cardiovascular outcomes, with UPMC agreeing to pay more if the drug outperforms expectations.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS124211

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel